Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
OncoC4, Inc.
Seagen Inc.
Pfizer
Aulos Bioscience, Inc.
Arcus Biosciences, Inc.
Sotio Biotech Inc.
Eli Lilly and Company
Pfizer
ViroMissile, Inc.
Tizona Therapeutics, Inc
Tasca Therapeutics
Clasp Therapeutics, Inc.
Brigham and Women's Hospital
Baylor College of Medicine
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
MacroGenics
City of Hope Medical Center
Daiichi Sankyo
Second Life Therapeutics
Ocellaris Pharma, Inc.
Var2 Pharmaceuticals
OncoNano Medicine, Inc.
University of Pittsburgh
RenJi Hospital
Cancer Research UK
NeoTX Therapeutics Ltd.
BicycleTx Limited
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Incyte Corporation
The Netherlands Cancer Institute
Totus Medicines
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
Genentech, Inc.
TransThera Sciences (Nanjing), Inc.
Cancer Research UK
NGM Biopharmaceuticals, Inc
Revolution Medicines, Inc.